SCRI-huCAR19

SCRI-huCAR19 is an investigational, second-generation chimeric antigen receptor (CAR) T-cell therapy developed by Seattle Children's Hospital for the treatment of pediatric and young adult patients with relapsed or refractory CD19+ B-cell malignancies, including leukemia and lymphoma. The therapy consists of autologous T cells (typically a 1:1 mixture of CD4+ and CD8+ cells) genetically engineered via lentiviral transduction to express a CAR construct. This construct features a fully human CD19-specific binding domain, a 4-1BB (CD137) costimulatory domain, and a CD3-zeta signaling domain. The use of a fully human binding domain is intended to reduce the risk of immune-mediated rejection of the CAR T cells, potentially enhancing their persistence and long-term efficacy. The therapy is currently being evaluated in the PLAT-06 clinical trial (Phase 1/2) and includes two versions, SCRI-huCAR19v1 and SCRI-huCAR19v2, both of which also incorporate a truncated HER2 (Her2tG) safety and tracking marker.

Other names

SCRI-huCAR19-Seattle Children's Hospital-leukemia-lymphomaCD19-specific CAR T cells with a fully human binding domainCD-19-specific CAR T cells with a fully human binding domainCD 19-specific CAR T cells with a fully human binding domain